While the inflammation-reducing and fibrosis-attenuating effects of glucagon agonism are less well-characterized, the reductions in hepatic inflammation parameters and fibrosis observed in preclinical models likely reflect secondary effects consequent to improved steatosis, rather than direct anti-inflammatory actions [21]
(Example: Check in for a B12 or Lipoden shot once a month)
Individual responses vary, and rapid weight loss or dehydration can temporarily stress the liver, which is why monitoring enzymes during treatment is useful
These mechanisms may support musculoskeletal repair, gastrointestinal healing, and reduced systemic inflammation, although results differ from person to person
Although these individuals have not been diagnosed with IgG4-related disease, their experiences reflect the real challenges faced by many who suffer from ongoing symptoms without clear answers